MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. 27. Juli 2016 Schmid, P., Ferreira, M., Dubey, S., Zaiss, M., Harper-Wynne, C., Makris, A., Brown, V., Kristeleit, H., Patel, G., Perelló, A., Jones, A., Mithal, N., Ruiz, I., Kümmel, S., Brunt, A.M., Guerra, J.A., Cao, M.G., Saura, C., Mousa, K., Sarker, S.-J., Coetzee, C., Swann, R., Cortes, J., 2016. Cancer Res 76(4 Supplement), OT1-03-12-OT1-03-12. doi:10.1158/1538-7445.SABCS15-OT1-03-12 Abstract Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma – a phase II trial. Mey, U.J.M., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T., Jehner, P., Rauh, J., Taverna, C.J., Schmid, M., Schmidt-Hieber, M., Doerfel, S., Fischer,… Weiterlesen Patient advocacy session: Registries, databases and statistical modelling. Making MBC count : The new German Cancer Registry. Marschner, N. 2017 The Breast, Volume 36, Supplement 1, 2017, Page S8. https://doi.org/10.1016/S0960-9776(17)30617-3… Weiterlesen